Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Researchers from the University of Oxford, together with colleagues across Europe as part of the ULTRA-DD Consortium (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) have established a novel approach to maximise the informativeness of genetic evidence for drug target prioritisation.

Leveraging genetics to help inform drug target discovery

In a paper published today in Nature Genetics, Professor Julian Knight at the Wellcome Centre for Human Genetics and colleagues from the ULTRA-DD Consortium shows how genetics and knowledge of networks can prioritise drug targets for immune-mediated diseases. 

The Priority Index or ‘Pi’ pipeline was developed by the study first-author Dr Hai Fang to be open-source and customisable, promoting collaborative efforts to accelerate early-stage drug development. This ethos was central to the ULTRA-DD Consortium, which included academic and pharma partners through an Innovative Medicines Initiative. A web interface allows users to visualise gene priority ratings, underlying data and analysis.

Read more (Wellcome Centre for Human Genetics website)